Treatment of EGFR-TKI resistant cells with the glucose analogue, 2-DG, improves the efficacy of the TKIs in EGFR mutated NSCLC models both in vitro and in vivo [9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.